Form 4: Aptevo Therapeutics Director Kunz Barbara Lopez Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Director Kunz Barbara Lopez reports acquisition of Aptevo Therapeutics Inc. common stock through vesting of restricted stock units.

Summary

  • On June 1, 2024, Director Kunz Barbara Lopez acquired 7 shares of Aptevo Therapeutics Inc. common stock through the vesting of restricted stock units (RSUs).
  • On June 2, 2024, the director acquired an additional 81 shares of common stock through RSU vesting.
  • The RSUs convert into common stock on a one-for-one basis.
  • The reported amounts reflect a 1-for-44 reverse stock split that occurred on March 5, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company director, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in beneficial ownership by a director.

Key Dates

DateDescription
June 1, 2021Reporting person was granted 893 (20 post-split) RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022.
June 1, 2022First vesting date of RSUs granted on June 1, 2021.
June 2, 2023Reporting person was granted 3,571 (81 post-split) RSUs, vesting in full on the first anniversary of the date of grant.
March 5, 2024Aptevo Therapeutics effected a 1-for-44 reverse stock split.
June 1, 2024Director acquired 7 shares of common stock through RSU vesting.
June 2, 2024Director acquired 81 shares of common stock through RSU vesting.
June 3, 2024Date of Form 4 filing.

Keywords

Aptevo Therapeutics, Director, Stock Transactions, Form 4, RSU, Reverse Stock Split, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.